LUNG CANCER STAGING
===================

The first American Joint Committee on Cancer (AJCC) lung cancer staging manual was published in 1977 ([@b3-molce-43-001]). The TNM was composed of T (tumor), N (lymph node), and M (metastasis) descriptors. Each of them can be in different combinations, each combination grouped on the basis of survival and referred to the same stage. In the three decades since, lung cancer staging has changed dramatically. The most recent manual, the Eight edition, developed by the International Association for the Study of Lung Cancer (IASLC) in 2015 and published by the Union for International Cancer Control (UICC) and the AJCC in 2016, is based on data collected between 1999 and 2010 from 94,708 patients including small cell and non-small cell lung cancer (NSCLC) treated in 35 institutions in 16 countries on five continents ([@b16-molce-43-001]). [Table 1](#t1-molce-43-001){ref-type="table"} outlines the detailed contents of the current one. Although the dataset is somewhat geographically biased (data from Europe, 49%; Asia, 44%; and North America, 5%), it remains the unique and official staging manual for lung cancer from the AJCC, UICC, and IASLC.

T (tumor) descriptors
---------------------

T descriptors consist of Tis, T1a(mi), T1, T2, T3, and T4. What was formerly called bronchioloalveolar carcinoma (BAC) was classified into Tis and T1a(mi); Tis refers to adenocarcinoma *in situ* (AIS), and T1a(mi) refers to minimally invasive adenocarcinoma (MIA) ([@b16-molce-43-001]). AIS is defined as a lung adenocarcinoma (LUAD) 3 cm or less in size, with a pattern of pure lepidic growth in which tumor cells proliferate along the surface of intact alveolar walls without stromal or vascular invasion. MIA is similar to AIS, but has a pattern of predominantly lepidic growth and an invasive component with a long axis shorter than 0.5 cm. T1 is subdivided into T1a (≤ 1 cm), T1b (\> 1 cm but ≤ 2 cm), and T1c (\> 2 cm but ≤ 3 cm). T2 is defined as a tumor of 3 to 5 cm in size or a tumor that has invaded the visceral pleura (the outer surface of the lung). T3 refers to tumors of 5 to 7 cm, and T4 is defined as a mass larger than 7 cm or a tumor that has invaded the diaphragm. Detailed information is provided in [Table 1](#t1-molce-43-001){ref-type="table"}.

N descriptors
-------------

The N descriptors consist of N0, N1, N2, and N3 ([Fig. 1](#f1-molce-43-001){ref-type="fig"}). N0 means no metastasis of the intrathoracic lymph node. N1 is defined as metastasis in the ipsilateral (i.e., on the same side as the main tumor), intrapulmonary, and peribronchial lymph nodes. N2 is defined as the presence of metastasis in ipsilateral mediastinal and/or subcarinal lymph nodes. N3 is any kind of lymph node metastasis beyond N2. Usually, the N descriptors are decided not by number, but by the location of the metastatic lymph node(s).

Although previously, the prognosis of N descriptors was considered to be independent of the number of metastatic lymph nodes, a recent proposal recommends that the number should be considered when determining stage; however, it was not adopted in the current manual ([@b4-molce-43-001]).

M descriptors
-------------

The M descriptors consist of M0, M1a, M1b, and M1c ([Fig. 1](#f1-molce-43-001){ref-type="fig"}). M0 indicates no metastasis except those in lymph nodes, whereas M1 refers to distant organ metastasis, and is subdivided into M1a, M1b, and M1c. M1a is defined as intra-thoracic metastasis, including pleural or pericardial effusions ([@b37-molce-43-001]). Moreover, separate and contralateral nodules with similar histology to the primary tumor can be classified as M1a. M1b refers to single extra-thoracic metastasis, and M1c to multiple extra-thoracic metastasis.

PATHOLOGIC, GENETIC, AND EPIGENETIC DESCRIPTORS TO CONSIDER FOR CANCER STAGING
==============================================================================

As can be seen in the latest version, the criteria for defining individual stage are overall survival rate and anatomic information. T stage is determined by size, location, invasion, and number: how large the malignant tumor is, where the mass is located, whether it invades, and how many tumors are present. N stage is determined by location, i.e., where the metastatic lymph nodes are located. M stage is determined by the location and number: of metastases inside or outside of the chest. The various combinations of T, N, and M, regardless of whether they are determined by computed tomography (CT) imaging or magnetic resonance imaging (MRI), are divided into subgroups based on survival rate. Each subgroup is defined as an independent stage.

However, the current staging system has some limitations. First, until now only anatomical data has been considered. It is natural that the principles of the TNM system classifies cancer cases into groups according to anatomical extent ([@b37-molce-43-001]). However, modern medicine has produced a great deal of information that leads to significant differences in the survival rates of lung cancer patients. Next, overall survival, which is used in the current system, can be meaningfully assessed only if the patient has received the best available treatment. In other words, the best survival rate of stage I NSCLC can be guaranteed if the patients have had a curative resection, whereas the best survival rates of stage II or III disease can be guaranteed if the patient had the standard treatment including chemotherapy and/or surgery/radiotherapy. However, if a patient with stage IV lung cancer who receives the latest medicine (tyrosine kinase inhibitor \[TKI\] or immune check point inhibitor) has the same chance of survival as a patient with stage I lung cancer, it is debatable whether this patient should be considered stage I or stage IV. Finally, the staging system focuses on the disease itself, rather than on the patient. The progression of disease, or stage of lung cancer, is the result of the interaction between the disease and the patient. It is widely accepted that the current TNM classification is a potent prognostic factor; however, the current approach to staging, which does not take the patient into account, is bound to have some limitations ([@b37-molce-43-001]). Therefore, we will describe the deficiencies in the current stage in terms of pathology, mutation, and epigenetic alteration ([Table 2](#t2-molce-43-001){ref-type="table"}).

Histopathologic information
---------------------------

Histologic grade, which is not addressed in the current staging system, is an important prognostic factor for lung cancers sized 20 mm or less ([@b22-molce-43-001]). Histologic grade is categorized into well-, moderately, and poorly differentiated carcinoma according to the degree of structural and cytologic atypia. In LUAD, 'poorly differentiated' (PD) is defined as a solid-pattern tumor without any clear gland formation, whereas in a squamous cell carcinoma, PD is defined as a solid-pattern tumor with a low degree of keratinization, intracellular bridges, and squamous pearl formation. PD status is the only independent factor identified as influencing overall survival, disease-specific survival, and disease-free survival in the study cited at the beginning of this section ([@b22-molce-43-001]). Therefore, adjuvant therapy should be considered in patients with PD lung cancer even if they are stage I.

Mitotic index is a strong prognostic factor for stage I LUAD ([@b12-molce-43-001]). A total of 145 cases of stage 1 LUAD were retrospectively reviewed by pathologists, who analyzed the specimens from these cases for predominant architectural pattern, nuclear grade, mitotic index, and necrosis. Mitotic activity was assessed by counting the number of mitoses within 10 high-power fields (HPFs), with the aim of counting 50 HPFs or five sets of 10 HPFs. For multivariate analysis, mitotic count was categorized as 0 to 10 or \> 10 mitoses per 10 HPF. Interestingly, stage (1A vs 1B) was not a prognostic factor in stage 1 LUAD, but mitosis count (over 10 per 10 HPF) was a significantly worse prognostic factor, with a hazard ratio (HR) of 4.58 (95% confidence interval = 1.893-11.11) in multivariate analysis ([@b45-molce-43-001]).

Mutations that influence prognosis
----------------------------------

Mutations of genes including *B-RAF* ([@b30-molce-43-001]), *EGFR* (epidermal growth factor receptor), *K-RAS* ([@b8-molce-43-001]), *RET* ([@b44-molce-43-001]), and *MET* ([@b9-molce-43-001]; [@b15-molce-43-001]) are used in determining the prognosis of lung cancer. In NSCLC patients with *B-RAF* mutations, metastasis of axillary lymph nodes frequently develops ([@b30-molce-43-001]). Axillary lymph nodes are not usually involved in lung cancer; consequently, the incidence of metastasis to these nodes in lung cancer patients is only 0.6% to 0.7% overall ([@b39-molce-43-001]; [@b40-molce-43-001]). However, in patients with *B-RAF* mutations, the incidence is much higher, about 15%. Therefore *B-RAF*--mutated lung cancer may represent a genetically distinct subgroup, requiring detailed physical examination.

A prospective study of a French cohort reported that *EGFR* and *K-RAS* mutations were prognostic factors for advanced lung cancer patients ([@b8-molce-43-001]). However, the prognosis differed in two ways depending on whether the EGFR or K-RAS mutation was employed. First, *EGFR* mutation was a prognostic factor for both overall and progression-free survival, whereas *K-RAS* mutation was significant only for overall survival. Second, *EGFR* mutation was a positive prognostic factor with an HR for overall survival of 0.7, whereas *K-RAS* mutation was a negative prognostic factor with an HR of 1.7. Moreover, because all patients in this study were treated with EGFR-TKI, the physiological significance of *K-RAS* mutation in TKI-naïve patients remains to be elucidated. However, other studies of *EGFR* copy number revealed that *EGFR* amplification had no significant effect on survival ([@b9-molce-43-001]).

*RET* rearrangement is a rare genetic change in lung cancer, occurring in 1% to 2% of cases. However, according to a recent report, it is detected in 2.4% of advanced lung cancers with malignant pleural effusion ([@b44-molce-43-001]). In that study, advanced lung cancer patients with malignant pleural effusion were divided into four groups: *RET* rearrangement, *EGFR* mutation, *K-RAS* mutation, and *ALK* rearrangement. The median overall survival of patients with *RET* rearrangement was 22.4 months, versus 21.3 months for patients with *EGFR*-mutant tumors. Notably, all patients with *EGFR* mutations were treated with EGFR-TKI, whereas kinase inhibitors were not administered to patients with *RET* rearrangement. Although the study population was limited to patients with malignant pleural effusion, the results suggest that the oncogenic activity of RET may be modest.

*MET*, which encodes the receptor for hepatocyte growth factor, is frequently overexpressed in NSCLC. Activation of *MET* stimulates cell--cell detachment, migration, and invasiveness ([@b7-molce-43-001]). In a retrospective study of 447 NSCLC patients who underwent radical tumor resection, high *MET* gene copy number (mean ≥ 5 copies per cell) was associated with worse prognosis than low copy number ([@b9-molce-43-001]). Another study of 180 NSCLC tissue microarrays revealed that MET fluorescence *in situ* hybridization (FISH) positivity was significantly associated with shorter survival, especially in squamous cell lung cancer (median overall survival, 49 months; *P* = 0.028) and stage III and IV disease (median overall survival, 23 months; *P* = 0.034) ([@b15-molce-43-001]). Multivariate analysis revealed similar results, but the effect was significant only in squamous cell carcinoma (HR = 2.330, 95% confidence interval = 1.151--4.713) ([@b15-molce-43-001]).

Epigenetic alterations
----------------------

Epigenetic abnormalities, including promoter hypermethylation, are involved in the prognosis of NSCLC. In this context, *RUNX3* (RUNX family transcription factor 3), *MGMT* (O-6-methylguanine DNA methyltransferase), and *RASSF1* (Ras association domain family member 1) have been investigated. Inactivation of Runx3 is a crucial event in the development of LUAD. [@b28-molce-43-001] demonstrated that targeted inactivation of *Runx3* induces lung adenomas and markedly shortens the latency of adenocarcinoma formation induced by oncogenic *K-RAS*. Moreover, aberrant inactivation of *RUNX3* is frequently detected in lung cancer tissue and is also associated with poor prognosis in lung cancer patients ([@b10-molce-43-001]; [@b34-molce-43-001]). The DNA repair gene *MGMT* is inactivated after methylation of *p16* gene, and this methylation prevents DNA repair of alkyl adducts, potentially leading to acquisition of somatic mutations in genes such as *TP53* ([@b46-molce-43-001]). Methylation of *MGMT* is detected more frequently in stage II to IV adenocarcinoma than in stage I ([@b35-molce-43-001]). Recent work showed that *RASSF1A* promoter hypermethylation is a prognostic marker in surgically resected NSCLC ([@b47-molce-43-001]). The authors of that study analyzed 101 (n = 68 in stage I, n = 33 in stage II, III) surgically resected NSCLCs and studied methylation in 10 genes including *RASSF1A*, *RUNX3*, *DAPK*, and *CDKN2A (p16)*. The frequencies of gene methylation were 42% for *RASSF1A*, 27% for *p16*, 26% for *DAPK*, and 25% for *RUNX3*. In patients with stage I disease, positive *RASSF1A* or *RUNX3* methylation status was associated with poor prognosis.

MOLECULAR EVENTS OF LUNG ADENOCARCINOMA TUMORIGENESIS
=====================================================

Stepwise progression of LUAD and molecular events
-------------------------------------------------

LUAD develops into invasive carcinoma through atypical adenomatous hyperplasia (AAH), AIS, and MIA ([@b33-molce-43-001]). Usually, early LUAD exhibits ground-glass opacity (GGO) in chest CT; a case report of a 10-year follow-up of GGO clearly depicted the stepwise progression of LUAD ([Fig. 2](#f2-molce-43-001){ref-type="fig"}) ([@b31-molce-43-001]). In that report, the authors made three important points. First, the tumor size of GGO does not reflect tumor invasion; instead, the size of the solid portion is a stronger determinant of tumor aggressiveness. GGO can be classified as pure or mixed: the former consists exclusively of GGO, whereas the latter consists of peripheral GGO and a central solid portion ([Fig. 2](#f2-molce-43-001){ref-type="fig"}). Second, routine 2-year follow-up may be insufficient for GGO nodules because they grow slowly. Third, positron emission tomography (PET) imaging is not an effective means of detecting pure GGO nodules because in contrast to typical LUAD, these nodules take up very little FDG (fluorine-18 labeled glucose), a marker of elevated metabolism and risk of malignancy. As shown above, because LUAD develops in a stepwise manner, it is associated not only with radiological changes, but also changes in the pathophysiology of the tumor. These changes can be attributed to various molecular events such as driver mutations and epigenetic alteration at each stage.

Alterations of *EGFR, KRAS*, and *TP53* have been confirmed as significant driver mutations of LUAD in many studies. Although these mutations are called drivers, this does not necessarily mean they are sufficient for tumor initiation. If they were, then their degree of their expression would have to be constant over the course of the various stages of LUAD. Instead, however, their expression tends to increase at later stages. A study of stage I LUAD in a Korean cohort ([@b49-molce-43-001]) found that the frequency of *EGFR* mutation increased with stage up (35% in AAH, 34.9% in AIS, and 49% in MIA). A gene panel study revealed that *EGFR* and *TP53* mutations were present, but were not predominant ([@b18-molce-43-001]): *EGFR* mutations were detected in 8% of AAH, 20% of AIS, and 75% of MIA. By contrast, *KRAS* mutations were detected in 12% of AAH, 20% of AIS, and 0% of MIA; and *TP53* mutations were detected in 8% of AAH, 7% of AIS, and 35% of MIA. A similar increasing trend in the frequency of oncogenic mutations and *TP53* mutation with tumor progression was also observed in a study based on whole-genome allelic imbalance scanning ([@b29-molce-43-001]; [@b32-molce-43-001]). Detailed data are shown in [Table 3](#t3-molce-43-001){ref-type="table"} and described in [Figure 3](#f3-molce-43-001){ref-type="fig"}.

As shown in [Table 3](#t3-molce-43-001){ref-type="table"}, not all cases of LUAD have a driver mutation in genes such as *EGFR*, *KRAS*, or *TP53*, although the frequency of driver mutations increases with stage. This phenomenon was also observed in a whole-exome sequencing study of 100 early lung cancers ([@b19-molce-43-001]). The results showed that mutations of *KRAS* (n = 26), *EGFR* (n = 13), and *TP53* (n = 29) mainly involved pre-genome doubling and/or clonal somatic events, although a minority were due to post-genome doubling or sub-clonal somatic events. In other words, it is possible that other molecular events occur prior to oncogenic driver mutation ([@b18-molce-43-001]). Therefore, it is necessary to pay attention to epigenetic alterations.

Stepwise progression of LUAD and epigenetic alteration
------------------------------------------------------

Epigenetic alteration, including promoter hypermethylation, is a crucial component of cancer initiation and progression ([@b5-molce-43-001]). Hypermethylation of many genes is a general characteristic of the cellular transformations leading to LUAD. In this context, *RUNX3*, *CDKN2A* (cyclin-dependent kinase inhibitor 2A), *DAPK*, *MGMT*, and *RASSF1* have been investigated. *RUNX3*, which plays indispensable roles in differentiation and also functions as a tumor suppressor, is frequently inactivated in multiple types of cancers ([@b17-molce-43-001]). Furthermore, recent data showed RUNX3 is frequently inactivated by down-regulation or mis-localization in human LUAD ([@b26-molce-43-001]; [@b28-molce-43-001]). In adult mouse lung, inactivation of *Runx3* induces lung adenomas of either the mucinous or non-mucinous type and accelerates progression of oncogenic *KRAS*--induced LUAD ([@b28-molce-43-001]). Development of LUAD is often associated with dysregulation of lung epithelial lineage--determining transcriptional regulators that govern differentiation status, and *RUNX3* is required for both bronchiolar and alveolar lineage differentiation ([@b17-molce-43-001]; [@b27-molce-43-001]). As a component of the p53-ARF pathways, *RUNX3* also plays a critical role in the defense against oncogene activation. When oncogenic *K-RAS* is constitutively activated, the RUNX3--BRD2 complex is maintained, and expression of *ARF* and *TP53* is prolonged until the G1/S checkpoint ([@b28-molce-43-001]). Thus, the RUNX3--BRD2 complex functions as a sensor for abnormal persistence of RAS activity ([@b28-molce-43-001]). However, inactivation of *RUNX3* disturbs these pathways, making cells vulnerable to activation of oncogenes such as *K-RAS*.

*CDKN2A* encodes two proteins of the INK4 family, p16 and p14-ARF. Both act as tumor suppressors by regulating the cell cycle. Hypermethylation of *CDKN2A* can occur early in the genesis of some premalignant lesions ([@b6-molce-43-001]), and methylation levels increase during disease progression from basal cell hyperplasia (17%) to squamous cell metaplasia (24%) to carcinoma *in situ* (50%). Interestingly, inactivation of *p16* has been detected in bronchial epithelial cells of cancer-free smokers.

*DAPK* encodes death-associated protein kinase, a serine/threonine kinase. Methylation of *DAPK* is detected in approximately 50% of alveolar hyperplasia induced in mouse lungs exposed chronically to NKK (tobacco-specific carcinogen 4-methylnitrosamino-1-(3-pyridyl)-1-butanone) ([@b36-molce-43-001]). Methylation of *MGMT* blocks DNA repair of alkyl adducts and can lead to acquisition of somatic mutations in genes such as *TP53* ([@b46-molce-43-001]). Methylation of *MGMT* was more developed in stage II to IV adenocarcinoma than stage I ([@b35-molce-43-001]). CpG island methylation of the *RASSF1A* promoter region was detected in 72% of small cell lung cancer and 34% of NSCLC ([@b1-molce-43-001]). Molecular studies revealed that *RASSF1A* suppresses the invasion and metastatic potential of human NSCLC by inhibiting activation of YAP (Yes-associated protein) through the GEF-H1/RhoB pathway ([@b11-molce-43-001]).

Epigenetic alteration and mutations according to LUAD progression
-----------------------------------------------------------------

Epigenetic alteration of multiple important genes could be a potent cause of early LUAD tumorigenesis ([@b21-molce-43-001]). [@b26-molce-43-001]; [@b28-molce-43-001] showed that inactivation of *Runx3* is frequently detected in mouse and human lung cancer tissue. Disruption of *p16* appears to be one of the earliest events involved in enabling clonal expansion ([@b6-molce-43-001]), and *DAPK* further aids in the development of autonomous premalignant clones. Subsequent loss of *MGMT* could lead to acquisition of somatic mutations in genes such as *TP53*, whose inactivation occurs at more advanced stages of pre malignancy ([@b46-molce-43-001]). These epigenetic alterations can result in driver mutations in genes such as *EGFR* and *K-RAS*, or create an environment that promotes the occurrence of these mutations (oncogenic activation). The activity of driver mutations accelerates cell division. This process is illustrated in [Figure 3](#f3-molce-43-001){ref-type="fig"}.

SUMMARY
=======

The current lung cancer staging system is the result of systematic studies using large-scale, long-term follow-up data ([@b13-molce-43-001]; [@b16-molce-43-001]; [@b38-molce-43-001]; [@b43-molce-43-001]). However, 40 years have passed since the first version of lung cancer staging was published, and it is to be expected that staging using only anatomical data will be subject to certain limitations. For example, among stage IV lung cancer patients, survival rates differ significantly depending on the presence or absence of *EGFR* mutation ([@b14-molce-43-001]; [@b20-molce-43-001]; [@b23-molce-43-001]; [@b38-molce-43-001]; [@b41-molce-43-001]; [@b48-molce-43-001]). Therefore, in order to achieve accurate lung cancer staging, it is necessary to consider a wide range of medical information in addition to anatomy.

LUAD progresses in a stepwise manner. Driver mutations in genes as *EGFR*, *K-RAS*, and *TP53* are involved in this progression, and epigenetic alterations also play important roles in tumorigenesis. However, not all cases of LUAD have apparent driver mutations. [@b48-molce-43-001] proposed four explanations for why not all LUAD follows a stepwise progression: i) the linear progression hypothesis could be applied to a subset of LUAD, according to a molecular classification; ii) the mutation rates of *EGFR* and *K-RAS* are not evenly distributed during progression; iii) some cases of LUAD revealed gene alterations discontinuous to invasive carcinoma; and iv) some lesions do not progress. In regard to driver mutations and epigenetic alterations, it is true that *EGFR*, *KRAS*, and *TP53* play important roles in lung tumorigenesis, but not all tumors develop by activating these mutations alone, and conversely, not all tumors can be eliminated solely by repressing these changes ([@b14-molce-43-001]; [@b20-molce-43-001]; [@b23-molce-43-001]; [@b41-molce-43-001]). Although the mutations described above have been called drivers, the mutations themselves might not be sufficient to drive lung cancer; instead, epigenetic alterations might cause a mutation to act as a true driver. Therefore, future lung cancer treatment should focus on both mutations and epigenetic alterations ([@b26-molce-43-001]; [@b28-molce-43-001]; [@b25-molce-43-001]; [@b47-molce-43-001]).
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![Atlas of lung cancer staging\
T factor is determined by size, location, invasion, and number of primary tumors. Location of metastatic lymph nodes defines the N factor. The M factor refers to metastasis: malignant pleural or pericardial metastasis is M1a, single extrathoracic metastasis is M1b, and multiple extrathoracic metastasis is M1c. These images and content are from the chapter 6 in the book of [@b37-molce-43-001]. Permission for use of this material was granted by IASLC.](molce-43-001f1){#f1-molce-43-001}

![Step-wise progression of LUAD\
Radiologically, LUAD develops from GGO (ground-glass opacity) to mixed and non-GGO. Pathologically AIS lesions progresses to MIA when invasion occurs. If the invasion exceeds 5 mm, then the MIA will progress to the next step. White arrow indicates pure GGO, and red arrow indicates the solid portion of a GGO nodule, yellow arrow indicates a non-GGO lung nodule.](molce-43-001f2){#f2-molce-43-001}

![Molecular events associated with the stepwise progression of LUAD\
In a series of processes from precancerous lesions to AIS, MIA, and invasive adenocarcinoma, epigenetic alterations such as *RUNX3* inactivation occur first (oncogenic initiation), and then driver mutations in genes such as *EGFR* and *K-RAS* are activated (oncogenic activation). Finally, the development of *TP53* mutation causes invasion and metastasis (oncogenic progression).](molce-43-001f3){#f3-molce-43-001}

###### 

Essentials of T, N, and M descriptors for the lung cancer and individual staging

  ------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------
  T descriptors (primary tumor)                     

   Tis                                              Carcinoma *in situ*

   T1                                               T1a(mi) -- Minimally invasive adenocarcinoma\
                                                    T1a -- tumor ≤ 1 cm in greatest dimension\
                                                    T1b -- tumor \> 1 cm but ≤ 2 cm in greatest dimension\
                                                    T1c -- tumor \> 2 cm but ≤ 3 cm in greatest dimension

   T2                                               Invasion of visceral pleura\
                                                    T2a -- tumor \> 3 cm but ≤ 4 cm in greatest dimension\
                                                    T2b -- tumor \> 4 cm but ≤ 5 cm in greatest dimension

   T3                                               Separate nodule in the same lobe (primary tumor)\
                                                    Invasion of chest wall (including parietal pleura), phrenic nerve, pericardium\
                                                    Tumor \> 5 cm but ≤ 7 cm in greatest dimension

   T4                                               Separate nodule in a same side (primary tumor) but a different lobe\
                                                    Invasion of diaphragm, mediastinum, heart, trachea, and esophagus, etc.\
                                                    Tumor \> 7 cm in greatest dimension

  N descriptors (regional lymph node involvement)   

   N0                                               No lymph node metastasis

   N1                                               Metastasis in ipsilateral peribronchial, hilar, or intrapulmonary lymph node(s)

   N2                                               Metastasis in ipsilateral mediastinal or subcarinal lymph node(s)

   N3                                               Metastasis in scalene, supraclavicular, or contralateral mediastinal, hilar lymph node(s)

  M descriptors (distant metastasis)                

   M0                                               No distant metastasis

   M1a                                              Separate tumor nodule(s) contralateral lobe or pleural/pericardial nodule or malignant pleural/pericardial effusion

   M1b                                              Single extrathoracic metastasis

   M1c                                              Multiple extrathoracic metastasis in one or more organs

  Individual staging                                

   Stage 0                                          TisN0M0

   Stage I                                          T1, T2a with N0M0

   Stage II                                         T2b, T3 with N0M0\
                                                    T1, T2 with N1M0

   Stage III                                        T4N0M0\
                                                    T3N1, T4N1\
                                                    Any T, N2-3M0

   Stage IV                                         Any T, Any N, M1
  ------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------

###### 

Important factors not addressed in the current staging method

  Title                         Factors                                          Clinical implications
  ----------------------------- ------------------------------------------------ -----------------------------------------------------------------------------
  Histopathologic information                                                    
   Grade                        Poorly differentiated                            Worse prognostic factor for NSCLC (\< 20 mm)
   Mitosis                      Mitosis count (\> 10/10 HPF)                     Worse prognostic factor for stage I NSCLC
  Mutations of prognosis                                                         
   *BRAF*                       V600E                                            High incidence of axillary lymph node metastasis
   *EGFR*                       Mutations in exon 18, 19, or 21                  Better prognostic factor for survival
   *KRAS*                       Mutations in exon 2                              Worse prognostic factor for survival
   *RET*                        *RET* rearrangement                              Better prognostic factor for survival
   *MET*                        Gene copy number variations (\> 5 copies/cell)   Worse prognostic factors, especially in squamous cell or stage III/IV NSCLC
  Epigenetic alterations                                                         
   *RUNX3*                      Inactivation                                     Worse prognostic factor
   *MGMT*                       Methylation                                      More developed in stage II--IV
   *RASSF1A*                    Methylation                                      Shorter duration of survival

###### 

Stepwise progression of LUAD and associated molecular events

  Authors                               Population                    AAH (%)   AIS (%)   MIA (%)   LUAD (%)
  ------------------------------------- -------------------- -------- --------- --------- --------- ----------
  Pre-malignant to minimally invasive                                                               
  [@b49-molce-43-001]                   AAH (n = 20)         *EGFR*   35        35        49        
                                        AIS (n = 43)                                                
                                        MIA (n = 47)                                                
  [@b18-molce-43-001]                   AAH (n = 25)         *EGFR*   8         20        75        
                                        AIS (n = 20 zones)   *KRAS*   12        20        0         
                                        MIA (n = 15 zones)   *TP*53   8         7         35        
  [@b32-molce-43-001]                   AIS (n = 15)         *EGFR*             67        68        
                                        MIA (n = 40)         *KRAS*             13        8         
                                        LUAD (n = 17)        *TP*53             13        53        
  [@b29-molce-43-001]                   AIS (n = 11)         *EGFR*             17        17        
                                        MIA (n = 25)         *KRAS*             2         10        
                                        LUAD (n = 6)         *TP*53             0         21        
  LUAD                                                                                              
  [@b2-molce-43-001]                    Stage I (n = 106)    *TP*53                                 55
  [@b24-molce-43-001]                   Stage I (n = 127)    *EGFR*                                 51
                                                             *KRAS*                                 11
  [@b42-molce-43-001]                   Stage I (n = 569)    *KRAS*                                 63
                                                             *TP*53                                 42

[^1]: These authors contributed equally to this work.
